# Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH

Study · id `cardio:ct-nct04702490` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04702490](<https://clinicaltrials.gov/study/NCT04702490>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04702490

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 120 participants.

## Technical summary

Registry record NCT04702490. Randomized; quadruple masking; primary purpose treatment. Start 2020-12-15 (actual); primary completion 2022-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 120 participants (enrolled count; ClinicalTrials.gov record NCT04702490, source copy `cardio:ctgov-nct04702490-2021-06-01`, retrieved 2026-10-26)
- Started: 2020-12-15 (actual) (ClinicalTrials.gov record NCT04702490, source copy `cardio:ctgov-nct04702490-2021-06-01`, retrieved 2026-10-26)
- Primary completion: 2022-04 (anticipated) (ClinicalTrials.gov record NCT04702490, source copy `cardio:ctgov-nct04702490-2021-06-01`, retrieved 2026-10-26)
- Completion: 2022-06 (anticipated) (ClinicalTrials.gov record NCT04702490, source copy `cardio:ctgov-nct04702490-2021-06-01`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT04702490, source copy `cardio:ctgov-nct04702490-2021-06-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04702490-2021-06-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH
- Condition: NASH
- Condition: NASH - Nonalcoholic Steatohepatitis
- Condition: Type 2 Diabetes
- Condition: Diabetes Type 2
- Condition: Diabetes
- Condition: Fatty Liver
- Condition: Fatty Liver, Nonalcoholic
- Condition: NAFLD
- Intervention (Drug): MET409 Active
- Intervention (Drug): MET409 Placebo
- Intervention (Drug): Empagliflozin
- Lead sponsor: Metacrine, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)

## Provenance

Content hash: 483a54afb3568f23f5998c06d800df1017e8faf7de6fc47092091cf2ae897936
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
